Renovis — FY2007 Earnings Presentation
58 slides from Renovis's earnings presentation, Mar 28, 2008
Slide 1: Evotec AG FY 2007 Results Presentation
Evotec AG FY 2007 Results Presentation, March 28, 2008 Filed by: EVOTEC AG Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Renovis, Inc. Exchange Act File No. 000-50564
Slide 2: Forward-looking statements
Forward-looking statements Folie Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. Such forward- looking statements include, but are not limited to, statements about the anticipated benefits of our products, the consumm
Slide 3: Agenda
Agenda Folie Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 4: Highlights 2007
Highlights 2007 Folie Transition to a global biopharmaceutical company Merger agreement signed with Renovis, shareholder approval expected May 01, 2008 Divestment of non-core assets for cash Clinical progress EVT 201 preclinical and POC data suggest strong efficacy and safety profile EVT 302 Phase I
Slide 5: Financial guidance for 2007 achieved
Financial guidance for 2007 achieved 94 (11) 37 33 54 2007** 01 Highlights 2007 93 – +19 % Liquidity at year end – +60 % (28) Net income – +10 % R&D expenses 30 – -19 % - Continuing business*** – -36 % Revenues Guidance 2006* Evotec Group (in € m) *** 2006 excl. ET/CPD 2007 excl. CPD ** Chemical Dev
Slide 6: Strategic transformation
Libraries Strategic transformation Renovis Discovery and Development Evotec Discovery and Development Screening Technologies Chemical Development, Formulation Services € 24 m CNS Pain Inflammation € 141 m cash* * Based on end of December 2007 cash, after expected transaction costs. 01 Highlights 200
Slide 7: Agenda
Agenda Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 8: EVT 201: Strong Proof-of-Concept Data in 2007
EVT 201: Strong Proof-of-Concept Data in 2007 Partial positive allosteric modulator for GABA A receptors Phase II results Successfully completed in 2007 Data reviewed with members of a key opinion leader panel Results offer great potential for a new treatment of insomnia Partnering Data in discussio
Slide 9: Market need
Market need Datamonitor report on insomnia April 2007 5 areas of unmet need identified 1: Reduction of residual daytime sedation 2: More effective treatments for insomnia in the elderly 3: Improvement in sleep maintenance 4: Lack of potential for tolerance and addiction 5: More effective treatments
Slide 10: EVT 201's best-in-class profile
Our assessment of EVT 201’s best-in-class profile: Expected differentiation on safety & efficacy Best-in-class potential on safety & efficacy Longer duration of action, more sustained effect in the 2nd half of the night vs Ambien CR, continued dosing leads to tolerance pPAM pharmacology expected to
Slide 11: Principal Investigator Dr James Walsh
Principle Investigator Dr James Walsh Executive Director of the Sleep Medicine and Research Center, St John’s Mercy Medical Center “EVT 201 appears to have an ideal pharmacokinetic profile and dose relationship to promote sleep induction and sleep maintenance for 7-8 hours, without risk of daytime s
Slide 12: EVT 302: Good safety data and start of Phase II
EVT 302: Good safety data and start of Phase II Selective MAO-B inhibitor for smoking cessation & Alzheimer’s Multiple ascending dose study in healthy subjects successfully completed Well tolerated in young & elderly up to the highest dose levels No significant adverse events or concerns from all sa
Slide 13: EVT 302: PET study successfully completed
EVT 302: Single ascending and multiple dose PET study successfully completed Dose selected for Phase II quit rate study Single ascending dose PET study in 18 healthy subjects dosed up to 15 mg Dose dependent occupancy and complete blockade of MAO-B achieved in relevant areas of brain Potency of EVT
Slide 14: EVT 302: Phase II quit rate study to start in H2
EVT 302: Phase II proof-of-concept quit rate study to start in H2 Design in progress 8 weeks treatment in smokers withdrawing from cigarettes 4 groups in parallel design – estimated patient number EVT 302 once daily, placebo, with and without nicotine replacement therapy Commonly used endpoints 4 we
Slide 15: EVT 101: Phase Ib higher repeat dose study
EVT 101: 4 week Phase Ib higher repeat dose cognition study, dosing completed Demonstrated concentrations in the CSF which are extrapolated to produce occupancy of the NR2B receptor in the anticipated therapeutic range and significantly greater than memantine NMDA occupancy Study conducted in France
Slide 16: EVT 101: Brain imaging fMRI study completed
EVT 101: Brain imaging fMRI study in healthy volunteers completed Modulation of the activity of specific brain regions during the performance of cognitive tasks Increase in baseline regional blood flow in the anterior cingulate cortex Provides first evidence of effect upon brain in man Modulation of
Slide 17: Phase Ib fMRI study: EVT 101-induced changes in rCBF
Phase Ib fMRI study: EVT 101-induced changes in rCBF 02 Pipeline Update
Slide 18: EVT 101: Progress in response to FDA IND review
EVT 101: Progress in response to FDA IND review Additional preclinical studies requested by FDA have been initiated Studies progressing to plan and expectations Start of single dose spinal cord injury associated neuropathic pain study in US dependent on these results and their review by FDA 02 Pipel
Slide 19: EVT 101: Summary of progress
EVT 101: Summary of progress Phase I fMRI study completed and reported today; dosing in 4 week higher repeat dose study completed At a dose level which was safe and well tolerated EVT 101 demonstrated penetration into the CSF to occupy NR2B receptors to a significantly higher level than memantine at
Slide 20: Progress on additional development programs
Progress on additional development programs EVT 103 Preclinical toxicology completed satisfactorily Progression to Phase I planned – timing dependent on budget Renovis P2X7 antagonist Preclinical toxicology completed satisfactorily Planned first in human Phase I study mid 2008 Renovis VR1 antagonist
Slide 21: Agenda
Agenda Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 22: Our Collaborations
Research results for a top quality customer network 03 Our Collaborations
Slide 23: Strategic progress
Strategic progress Higher value and strategic deals in preferred therapeutic areas Boehringer Ingelheim collaboration extended for another year Significant expansion of CHDI collaboration in Huntington‘s Disease Expansion of DAC collaboration into medicinal chemistry phase Technical differentiation
Slide 24: High-value added, results-based collaborations
High-value added, results-based collaborations Deliver preclinical candidates exploiting Evotec’s GPCR and other target class expertise 76 FTE committed (36 from Evotec) Duration 6 years Extended in 2008 for another year Research payments, milestones, royalties, rights back CNS project on undisclose
Slide 25: Substantial contracts in preferred therapeutic areas
Substantial contracts in preferred therapeutic areas Three-year extension of integrated drug discovery contract in Huntington‘s Disease Worth up to US $ 37m Covers Evotec’s entire drug discovery offering Example for strategic expertise in CNS Biology and medicinal chemistry support Continued into th
Slide 26: Fragment-based platform EVOlution leads to new deal flow
Fragment-based drug discovery platform EVOlution™ leads to significant new deal flow Collaboration on HSP90 advanced well into lead optimization based on fragment-based approach Validation phase completed generating novel IP Fragment-based drug discovery program yields positive results and leads to
Slide 27: Agenda
Agenda Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 28: Key financials 2007: Increased R&D investment
Key financials 2007: Increased R&D investment -58.1 -11.2 36.9 -48.1 -0.1 0.4 11.1 17.8 36.9 24.4% 32.9 2007 Actual 04 FY 2007 Results Condensed Profit & Loss Statement (IFRS) – continuing business in €m -68% -34.5 Operating income (loss) +60% -27.7 Net income (loss) total – 1.3 Net income (loss) di
Slide 29: Revenues impacted by library JV and absence of milestones
Revenues impacted by library JV and absence of milestone payments in 2007 04 FY 2007 Results 2006 2007 Trad.Revenues Library Milestones 3.2 Revenues, continuing business (in € m) 40.6 30.8 32.0 6.6 0.9 32.9
Slide 30: Adjusted for FX ongoing business increased by 9%
Adjusted for foreign exchange ongoing business increased by 9% 04 FY 2007 Results 2006 2007 Trad.Revenues FX-effect Revenues, continuing business (in € m) 32.0 1.5 33.5 30.8
Slide 31: Milestone payments lead to margin volatility
Milestone payments lead to margin volatility Milestone impact: € 3.2m milestones improved GM in 2006 by 6% Currency effect due to weak USD : -3%-points Different revenue-mix towards higher risk milestone-earning projects Group gross margin, continuing business (in %) 33.9% 24.4% 2006 2007 04 FY 2007
Slide 32: Research & Development: Creating pipeline value
6.6 Research & Development (R&D): Creating pipeline value 23.7 30.3 36.9 2006 2007 Group In-licensing 2007: - €36.9m for proprietary R&D (Discovery: 23% / Clinical Development: 64%) 2006: - €23.7m for proprietary R&D (Discovery: 24% / Clinical Development: 57%) - €6.6m spend for in-licensing of EVT
Slide 33: Higher operating loss mainly due to lower GP and R&D
Higher operating loss mainly due to lower GP, increased R&D investment & impairment 2006 2007 -34.5 -58.1 * 2006 as restated 04 FY 2007 Results Operating result, continuing business* (in € m) Amortization & impairment Net income before amortization & impairment € -0.6m Reversal of impairment € 3.3m
Slide 34: Net income improved by divestment of ET and CPD
Net income in 2007 improved by the divestment of ET €11.2m CPD € 25.2m -11.2 -27.7 Net Income improved by 60% 2006 2007 * 2006 as restated 04 FY 2007 Results Net loss, total business* (in € m)
Slide 35: Chemical Development Business: Discontinued operations
Chemical Development Business, sold to Aptuit effective November 30, 2007 : Discontinued operations 2.3 2.3 0.0 0.0 3.1 0.0 25.5% 21.5 2007 Actual* 04 FY 2007 Results Condensed Profit & Loss Statement (IFRS) – Chemical Development Business (CPD) in €m +194% -2.5 Operating income (loss) -43% 4.1 Oper
Slide 36: Cash development 2007
Cash development (incl. investments) 2007*: Cash flow from operations dominated by R&D expenditure 18.9 42.5 78.7 -33.4 93.7 -8.8 -1.1 -3.1 in € m Cash 31.12.06 Other investing & financing CF Acquisition Neuro3d Cash 31.12.07 FX effect Operating CF Sale of CPD Business Capex excl. finance leases 04
Slide 37: Sharpening the focus on proprietary research
Sharpening the focus on proprietary research 299 554 566 38 87 53 Growing R&D discovery operations 2005 2006 2007 Services Pharma 04 FY 2007 Results Employees as of Dec 31, year-end, total business
Slide 38: Reduced asset base due to divestments
Reduced asset base due to divestments 93.9 34.7 20.1 15.7 78.7 77.5 18.5 18.2 93.7 04 FY 2007 Results Balance sheet – Assets* (in € m) Dec 31, 2006 Dec 31, 2007 243.1 207.9 * 2006 as restated Intangible assets + other long-term assets Property, plant and equipment Assets classified as held for sale
Slide 39: Capital expenditures handled restrictively
Capital expenditures handled restrictively, includes € 1.1m acquired assets from Combinature 04 FY 2007 Results * Without finance leases 3.1 0.2 ** 2006 as restated Capital expenditures – continuing business * / ** (in € m) 3.5 2.9 2006 2007 Purchase PPE (fixed assets) Purchase intangible assets
Slide 40: Equity ratio increased to 82%
Equity ratio increased to 82% Thereof 22.2m liability to deliver ET (equiv. to prepayment) 04 FY 2007 Results Balance sheet – Liabilities & stockholders’ equity* (in € m) Dec 31, 2006 Dec 31, 2007 243.1 207.9 * 2006 as restated Stockholders‘ equity Long-term liabilities and deferred taxes Liabilitie
Slide 41: Agenda
Agenda Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 42: Renovis history
Renovis history 2004 IPO: 3 clinical programs Lead program in stroke, positive data in May, 2005 Wall Street “ darling ” until October 2006 with pivotal trial failure Peak market cap: ~$700 million 2006 Re-start: Trading at cash, <$100 million Down-sizing, top management departed Focused, integrated
Slide 43: The combination: Multi-faceted pipeline
The combination: Multi-faceted pipeline, strong fit and differentiating science EVT 201 GABA A receptor partial positive modulator for Insomnia EVT 302 MAO-B inhibitor – Smoking Cessation, Alzheimer‘s EVT 101 NMDA NR2B subtype selective antagonist – Alzheimer‘s, Pain EVT 103 NMDA NR2B subtype select
Slide 44: VR1 - Vanilloid Receptor antagonist: Pfizer collaboration
VR1 - Vanilloid Receptor 1 antagonist Exclusive worldwide collaboration Pooled program signed Q2 2005 >$20m+ lic. fees & research funding $170m+ milestones possible for each product candidate $1.5m milestone payment (2006) $4.5m milestone payment (2007) Double-digit royalties on w/w net sales Two-ye
Slide 45: VR1 - Potential for safe, best-in-class analgesic
VR1 - Vanilloid Receptor 1 antagonist Potential for safe, best-in-class analgesic, non-addictive, minimal side effects Clinical & preclinical validation for pain Competitive R&D activity Potentially ideal drug profile… Strong analgesic Non-addictive Minimal side effects Broadly applicable analgesic
Slide 46: P2X receptor antagonist
P2X 7 receptor antagonist Potential best-in-class molecule Strong industry interest Best-in-class opportunity Multiple large potential indications Pain, RA, IBD, COPD Clinical candidate & back-up series Planned Phase 1 in 2008 Partnering opportunity 05 The Merger with Renovis
Slide 47: P2X 2/3 receptor antagonist
P2X 2/3 receptor antagonist Validated for multiple pain types Strong industry interest: 1 st -in-class Lead series with superior properties Multiple large potential indications Inflammatory pain Neuropathic pain Urinary incontinence Planning Phase 1 in H1 2009 05 The Merger with Renovis
Slide 48: Key facts on Renovis acquisition
Key facts on Renovis acquisition Data pro-forma Merger close Form F-4 declared effective by the SEC in March 2008 NASDAQ listing expected in May 2008 Closing subject to shareholder vote on May 01, 2008 34.57m Evotec shares exchanged for 32.79m Renovis shares Fixed share exchange rate of 1.0542 EVT f
Slide 49: Key anticipated benefits
Key anticipated benefits Operational footprint in leading biotech region – Bay Area in the US Strong inflammation / pain talent pool Academia Expansion / de-risking of pipeline Several significant value inflection points in 2008/2009 Pipeline funding NASDAQ liquidity 05 The Merger with Renovis
Slide 50: High-value and strategic partnerships
High-value and strategic partnerships: Milestones expected in 2008, 2009 Post-merger partnership profile 76 FTEs, 6 year collaboration, milestones, royalties CNS target, milestones > €100 m, mid-single digit royalties VR1, US$ 10m in upfront payment, >US$ 10m in FTE funding, >US$ 170m milestones, do
Slide 51: Agenda
Agenda Highlights 2007 Pipeline Update Collaborations FY 2007 Results The Merger with Renovis Outlook 2008
Slide 52: Sales and Order Book
Sales and Order Book 19.2 19.1 06 Outlook 2008 2008 Sales and Order Book, continuing business Status as of February (in € m) 2007 2008
Slide 53: Financial guidance 2008 (incl. Renovis)
Financial guidance 2008 (incl. Renovis) Liquidity Dec 31, 2008 excluding out-licensing payments : > €85m R&D expenses before employee stock compensation : €46m - €51m Revenues before out-licensing income : €34m - €36m 06 Outlook 2008 Cash run at least 3 years - assumes no major out-licensing event P
Slide 54: Our research plan 2008 (incl. Renovis)
Our research plan 2008 (incl. Renovis) Start / completion of POC Phase II studies in Smoking Cessation EVT 302 3-4 lead optimisation projects Discovery Start of Phase I studies P2X7 No R&D / funded by Pfizer VR1 Subject to successful out-licensing of EVT 201 or others EVT 103 Completion Phase Ib stu
Slide 55: Combined newsflow 2008
Combined newsflow 2008 H1 2008 H2 2008 NASDAQ listing ( ) EVT 101: - Ph Ib fMRI cognition data - Ph Ib higher repeat dose data EVT 302: - Ph I safety d ata - Single / repeat dose PET data - Initiate Ph II craving study Partnership EVT 201 EVT 302: - Initiate Ph II quit rate study - Ph II craving dat
Slide 56: Major value inflection points by end 2009
Major value inflection points by end 2009 Partnering opportunity for EVT 201 in 2008 Phase II POC data for EVT 302 in 2008/2009 Craving study Quit rate study Phase II POC data for EVT 101 in 2009 Depending on start and final study design Entry of several drug candidates into Phase I studies in 2008/
Slide 57: A compelling CNS investment
A compelling CNS investment Global CNS pure play Lead insomnia compound EVT 201 Partner-ready, best-in-class Broad and deep pipeline, with clinical momentum Proprietary and partnered Fully integrated discovery-through-development core competencies Multiple partners generating collaborative revenues:
Slide 58: Tomorrow's Drugs Today
Tomorrow’s Drugs Today™ Your contacts: Jörn Aldag President & CEO P: +49.(0)40.56081-375 joern.aldag@evotec.com Anne Hennecke SVP, Investor Relations P: +49.(0)40.56081-286 anne.hennecke@evotec.com